ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Kinnate Biopharma Inc

Kinnate Biopharma Inc (KNTE)

2.65
0.00
( 0.00% )
Actualizado: 19:00:00

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
2.65
Postura de Compra
2.64
Postura de Venta
2.65
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Precio Anterior
2.65
Precio de Apertura
-
Hora
Última hora de negociación
-
Volumen promedio (3 m)
-
Volumen financiero
-
Precio Promedio Ponderado
-

KNTE Últimas noticias

XOMA Corporation Announces Closing of Tender Offer

EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech...

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (“XOMA” or the “Company”; Nasdaq: XOMA) entered into a merger agreement to...

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories PR Newswire CASTRES, France and SAN FRANCISCO, March 1, 2024 Kinnate has entered into...

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.The transaction is in furtherance...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
CNEYCN Energy Group Inc
US$ 0.9599
(65.53%)
177.63M
ONCOOnconetix Inc
US$ 5.23
(55.87%)
28.98M
CNETZW Data Action Technologies Inc
US$ 0.926
(44.69%)
22.06M
TCTMTCTM Kids IT Education Inc
US$ 1.29
(35.79%)
5.12M
UXINUxin Ltd
US$ 3.64
(28.62%)
1.96M
ICGIntchains Group Ltd
US$ 5.10
(-39.86%)
1.5M
EDBLEdible Garden AG Inc
US$ 0.2801
(-39.79%)
2.94M
NVNOenVVeno Medical Corporation
US$ 3.3899
(-24.67%)
1.23M
MNTSMomentus Inc
US$ 0.4242
(-20.86%)
2.21M
IVPInspire Veterinary Partners Inc
US$ 0.4751
(-20.68%)
2.21M
CNEYCN Energy Group Inc
US$ 0.9599
(65.53%)
177.63M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.1528
(11.86%)
172.76M
XPONExpion360 Inc
US$ 0.0803
(24.69%)
143.7M
NVDANVIDIA Corporation
US$ 119.842
(-3.38%)
112.94M
DUOFangDD Network Group Ltd
US$ 1.18
(10.28%)
65.05M

Su Consulta Reciente

Delayed Upgrade Clock